Idorsia biopharmaceutical company has placed CHF 600 million senior unsecured convertible bonds due 2028 in a private placement with institutional investors. The net proceeds of the
Baitella Beteiligungen, the holding company of Baitella, a provider of user-friendly, individualized holding system solutions with central clamping unit, was acquired by RN Acqui III, a subsidiary of Renaissance Evergreen, for an undisclosed consideration. The
Julius Baer Group has finalized the acquisition of a 83% stake in Kuoni Mueller and Partner Holding, an integrated real estate service provider based in Zurich. Schellenberg Wittmer acted as legal counsel to Baer Group
H.C. Wainwright acted as sole placement agent in connection to the private placement of 71,428,572 shares in Relief Therapeutics Holding, a Swiss biopharmaceutical company listed at SIX Swiss Exchange, at a price of CHF 0.21 per
Glatfelter Corporation, a global supplier of engineered materials, has entered into a definitive agreement to acquire the Jacob Holm Group, a manufacturer of spunlace nonwoven fabrics headquartered in Basel, Switzerland, for an enterprise value of
TX Markets is taking over the real estate portal Acheter-Louer.ch & Publimmo CRM system, from private individuals. With this acquisition, TX Markets is expanding its real estate marketplace portfolio. Walder Wyss advised the
Homburger acted as counsel to Dz Bank -Deutsche Zentral-Genossenschaftsbank, Frankfurt am Main, as arranger, agent, security agent and lender in connection with certain financing aspects of the acquisition of zvoove Switzerland (formerly BackOffice) by zvoove
Swiss Post, the national postal service of Switzerland, has acquired a majority stake in established file sharing company Tresorit, a provider of encrypted productivity solution for secure collaboration, combining patented end-to-end encryption (E2EE) and
AC Immune, a clinical-stage biopharmaceutical precision medicine company for neurodegenerative diseases, announced it’s acquisition of Affiris’s portfolio of therapeutics targeting alphasynuclein (a-syn), notably Affiris PD01, a clinically-validated active vaccine candidate for the treatment
Allgeier, a technology company for digital transformation, agreed to purchase an 80% stake in MySign. The core business of Swiss-based MySign, a digitalization of business models with a focus on eCommerce. The investment will be made
